HK Stock MarketDetailed Quotes

06160 BEIGENE

Watchlist
  • 92.250
  • -1.750-1.86%
Market Closed Jul 19 16:08 CST
126.89BMarket Cap-20669P/E (TTM)

About BEIGENE Company

BeiGene GmbH's mission is to become a global leader in the discovery, development, and commercialization of innovative molecular-targeted immunologic drugs to treat cancer. BeiGene is a global, commercial-stage biotechnology company focused on the research, development, production and commercialization of innovative medicines. The company's products are mainly innovative drugs developed independently and innovated at the source. Through a collaborative approach of independent R&D and cooperative development, the company continues to expand its product pipeline. As of the signing date of this prospectus, the company's two drugs, BRUKINSA (BRUKINSA) and Baizean, have been conditionally approved for listing by the China Drug Administration, and BRUKINSA (BRUKINSA) has also received accelerated approval for listing by the US FDA.

Company Profile

Symbol06160
Company NameBEIGENE
ISINKYG1146Y1017
Listing DateAug 8, 2018
Issue Price108.00
Shares Offered65.60M share(s)
FoundedJun 28, 2018
Registered AddressCayman Islands
Chairmanleiqiang ou
Secretaryqingling zhou
Audit InstitutionErnst & Young LLP, Ernst & Young LLP
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeThe Neighbors of Mourant Governance Services (Cayman) Limited 94 Solaris Avenue Camana Bay Grand Cayman KY1-1108 Cayman Islands
Head Office and Principal Place of BusinessRoom 1901, 19th floor, Lee Garden Phase 1, 33 Hysan Avenue, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees10500
MarketHong Kong motherboard
Phone+1 (781) 801-1800;1 (877) 828-5568
Fax010-85148699
Emailir@beigene.com
Business BeiGene Ltd is a global biotechnology company dedicated to discovering and developing oncology treatments for cancer patients around the world. The company has discovered and developed three approved drugs, including BRUKINSA, a small molecule inhibitor of Bruton's tyrosine kinase to treat various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for various solid tumors and blood cancers; and pAMIParib, a selective small molecule inhibitor of polyADP ribose polymerase 1 (PARP1) and PARP2. The company has obtained approval to sell BRUKINSA in the US, the People's Republic of China (China), the European Union, the United Kingdom, Canada, Australia, and other international markets; sell tiralizumab in the EU and China; and sell pamipanib in China. It also focuses on commercializing cancer drugs such as XGEVA, BLINCYTO, KYPROLIS, etc. in China under the exclusive license of Amgen Inc.

Company Executives

  • Name
  • Position
  • Salary
  • leiqiang ou
  • Presidencies, CEOs, Executive Director, Authorized Representative
  • 16.74M
  • xiaodong wang
  • Non-executive Directors
  • 4.27M
  • Olivier Brandicourt
  • Independent Non-Executive Director, Audit Committee Members
  • --
  • Margaret Han Dugan
  • Independent Non-Executive Director, Remuneration Committee Chairman, Member of the Advisory Committee on Commercial and Medical Affairs
  • 516.00K
  • Donald W. Glazer
  • Independent Non-Executive Director, Chairman of the Nomination and Corporate Governance Committee
  • 486.00K
  • Michael Goller
  • Independent Non-Executive Director, Nomination and Corporate Governance Committee Members
  • 487.00K
  • Anthony C. Hooper
  • Independent Non-Executive Director, Chairman of the Audit Committee, Nomination Committee Members
  • 518.00K
  • Ranjeev Krishana
  • Independent Non-Executive Director, Remuneration Committee Members
  • 492.00K
  • Alessandro Riva
  • Independent Non-Executive Director, Nomination Committee Members
  • 497.00K
  • Corazon (Corsee) D. Sanders
  • Independent Non-Executive Director, Audit Committee Members
  • 507.00K
  • qingqing yi
  • Independent Non-Executive Director, Remuneration Committee Members
  • 492.00K
  • xiaobin wu
  • President, General Manager, Chief Operating Officer
  • --
  • lai wang
  • Head of Global R&D
  • --
  • Chan Lee
  • Senior Vice President, General Counsel
  • --
  • qingling zhou
  • Authorized Representative, Company Secretary
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg